Literature DB >> 7730496

Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: role of 5-HT2 receptor and alpha 1-adrenoceptor antagonism [corrected].

T H Svensson1, J M Mathé, J L Andersson, G G Nomikos, B E Hildebrand, M Marcus.   

Abstract

In experiments in rats, by the use of single-cell recordings from midbrain dopamine (DA) neurons of the ventral tegmental area (VTA), the systemic administration of the schizophrenomimetic N-methyl-D-aspartate receptor antagonists phencyclidine (PCP) or dizocilpine (MK-801) caused an increased firing rate but reduced the variability of firing in VTA DA neurons. Burst firing was increased in cells predominantly located in the paranigral nucleus, a subdivision of the VTA largely projecting to the nucleus accumbens and other limbic regions, but reduced in DA cells predominantly located in the parabrachial pigmented nucleus, another subdivision of the VTA that projects largely to the prefrontal cortex (PFC). Thus, a severely impaired signal-to-noise ratio within the PFC DA projection was obtained, concomitant with an overactive mesolimbic DA system. The administration of high doses of ritanserin or atypical neuroleptics with prominent serotonin (5-hydroxytrypyamine) 5-HT2 receptor antagonist action, such as clozapine or amperozide, produced preferential activation of the PFC DA projection. In contrast, the selective D2 receptor antagonist raclopride caused a greater activation of the subcortical than cortical DA projections, as assessed by microdialysis experiments in vivo from our laboratory. Adding ritanserin treatment to raclopride markedly enhanced the raclopride-induced increase in DA levels in the medial PFC, an effect probably mediated by augmentation of the raclopride-induced increase in the burst firing of meso-cortical DA neurons, but failed to affect the action of raclopride on striatal DA levels.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7730496     DOI: 10.1097/00004714-199502001-00003

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  19 in total

1.  Novel antipsychotics and the neuropsychological deficiencies of schizophrenia.

Authors:  K A Hawkins
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

2.  Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.

Authors:  A Schotte; P F Janssen; W Gommeren; W H Luyten; P Van Gompel; A S Lesage; K De Loore; J E Leysen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 3.  Substance abuse and schizophrenia: pharmacotherapeutic intervention.

Authors:  Alan I Green; Douglas L Noordsy; Mary F Brunette; Christopher O'Keefe
Journal:  J Subst Abuse Treat       Date:  2007-06-15

4.  Combined administration of an mGlu2/3 receptor agonist and a 5-HT 2A receptor antagonist markedly attenuate the psychomotor-activating and neurochemical effects of psychostimulants.

Authors:  Jason M Uslaner; Sean M Smith; Sarah L Huszar; Rashida Pachmerhiwala; Richard M Hinchliffe; Joshua D Vardigan; Pete H Hutson
Journal:  Psychopharmacology (Berl)       Date:  2009-08-26       Impact factor: 4.530

5.  Topiramate augments the antipsychotic-like effect and cortical dopamine output of raclopride.

Authors:  Amani Eltayb; Marie-Louise G Wadenberg; Björn Schilström; Torgny H Svensson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-11-12       Impact factor: 3.000

6.  A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia.

Authors:  Mary F Brunette; Ree Dawson; Christopher D O'Keefe; Meera Narasimhan; Douglas L Noordsy; Joanne Wojcik; Alan I Green
Journal:  J Dual Diagn       Date:  2011

Review 7.  Tobacco use among individuals with schizophrenia: what role has the tobacco industry played?

Authors:  Judith J Prochaska; Sharon M Hall; Lisa A Bero
Journal:  Schizophr Bull       Date:  2007-11-05       Impact factor: 9.306

8.  Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain.

Authors:  P Hertel; G G Nomikos; M Iurlo; T H Svensson
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 9.  Pharmacotherapy for schizophrenia and co-occurring substance use disorders.

Authors:  Douglas L Noordsy; Alan I Green
Journal:  Curr Psychiatry Rep       Date:  2003-10       Impact factor: 5.285

10.  The absence of 5-HT(1A) receptors has minor effects on dopamine but not serotonin release evoked by MK-801 in mice prefrontal cortex.

Authors:  Anna Castañé; Francesc Artigas; Analía Bortolozzi
Journal:  Psychopharmacology (Berl)       Date:  2008-07-02       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.